Abstract

Single-cell sequencing, which is used to detect clinically important tumor subpopulations, is necessary for understanding tumor heterogeneity. Here, we analyzed transcriptomic data obtained from 34 single cells from human lung adenocarcinoma (LADC) patient-derived xenografts (PDXs). To focus on the intrinsic transcriptomic signatures of these tumors, we filtered out genes that displayed extensive expression changes following xenografting and cell culture. Then, we performed clustering analysis using co-regulated gene modules rather than individual genes to minimize read drop-out errors associated with single-cell sequencing. This combined approach revealed two distinct intra-tumoral subgroups that were primarily distinguished by the gene module G64. The G64 module was predominantly composed of cell-cycle genes. E2F1 was found to be the transcription factor that most likely mediates the expression of the G64 module in single LADC cells. Interestingly, the G64 module also indicated inter-tumoral heterogeneity based on its association with patient survival and other clinical variables such as smoking status and tumor stage. Taken together, these results demonstrate the feasibility of single-cell RNA sequencing and the strength of our analytical pipeline for the identification of tumor subpopulations.

Highlights

  • Tumors are not identical between patients at the molecular or morphological/pathological level

  • Cleaning of the Transcriptomes of the 34 Single Cells Derived from lung adenocarcinoma (LADC) patient-derived xenografts (PDXs)

  • A tissue block from an LADC surgical sample was engrafted into immuno-compromised mice, and the xenograft tumors were cultured for tumor cell expansion, resulting in a total of 34 single cells

Read more

Summary

Introduction

Tumors are not identical between patients at the molecular or morphological/pathological level. This observation, often referred to as inter-tumoral heterogeneity, forms the basis of targeted cancer medicine [1,2,3]. Further tumor heterogeneity is present within a single patient; this phenomenon is defined as ‘intra-tumoral heterogeneity’ [4,5,6,7,8,9,10], and its clinical importance is increasingly being recognized [11,12,13,14]. Often harboring different genetic mutations, may have varying sensitivities to targeted treatments [15,16,17,18,19], and drug-resistant subclones may cause treatment failure.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call